Session	Start-ups/SMEs looking for Finance: Pre-seed/Angel/Seed
Title	Advancing bioconjugation with enzymatic precision
Company	Enzura Biotech
Speaker	Davide Carraretto
TRL	TRL 4 - 7
Keywords feedstock (max 2)	Recombinant proteins
Keywords technology (max 2)	Enzymatic bioconjugation
Keywords End-Product (max 2)	Protein conjugates

Abstract:

The booming market for targeted therapeutics, such as antibody-drug conjugates (ADCs), is constrained by current bioconjugation methods. Traditional chemistry yields unpredictable, potentially toxic drug mixtures, while current site-specific enzymatic alternatives require prohibitively expensive substrates, rely on long peptide tags that can destabilize proteins, or are structurally restricted to a single terminus.

To address these critical limitations, Enzura Biotech has developed a versatile, low-cost technology for site-specific protein functionalization, making bioconjugation simple, affordable, and accessible. A short peptide tag on the target directs our proprietary enzyme to install a click-ready chemical handle at a single programmable position: the N-terminus, C-terminus, or an internal loop. Any payload can then be attached using click chemistry. The click substrate itself is made in a one-pot enzymatic step from bulk, off-the-shelf reagents, without custom synthesis, protecting groups, or specialist suppliers."